Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

By sjmartinez • September 6, 2024

Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, Konicek BW, Kadziola Z, Nunez M, Brnabic A, Schuster C. Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Derm Venereol. 2024 Sep 5;104:adv40556. doi: 10.2340/actadv.v104.40556. PMID: 39235051.

Tags: Dermatology, Publications

US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and Venereology

Kasperkiewicz M, Thapa M, Adotama P, Tomayko MM, Culton DA. US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European[...]

Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus

Jiang R, Bogle R, Xing X, Kirma J, Fox J, Harms PW, Do T, Billi AC, Kahlenberg JM, Modlin RL, Teles R, West J, Mangold[...]

Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis

Conde G, Carmenate Y, Bello G, Armstrong AW. Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis. J Dermatol. 2026 Mar 13. doi:[...]